Quick Answer
Rallybio Corp reported Net Income Loss of -$8.98 million for the year ending 2025.
- Rallybio Corp showed an increase of +84.5% in Net Income Loss from 2024 to 2025.
- This data is from Rallybio Corp's annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$4.89 million | Q3 2020: -$7.16 million | Q1 2021: -$13.28 million | Q2 2021: -$11.13 million | Q3 2021: -$10.20 million | Q1 2022: -$14.50 million | Q2 2022: -$17.58 million | Q3 2022: -$18.37 million | Q1 2023: -$17.32 million | Q2 2023: -$18.63 million | Q3 2023: -$18.37 million | Q1 2024: -$19.03 million | Q2 2024: -$16.24 million | Q3 2024: -$11.47 million | Q1 2025: -$9.44 million | Q2 2025: -$9.70 million | Q3 2025: $16.02 million.
- Over the full 6 years of available data (2020 to 2025), Rallybio Corp's Net Income Loss has grown by 66.1%.
- Historical annual values: Fiscal year 2025: -$8.98 million | Fiscal year 2024: -$57.78 million | Fiscal year 2023: -$74.56 million | Fiscal year 2022: -$66.65 million | Fiscal year 2021: -$47.01 million | Fiscal year 2020: -$26.45 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: